Maria Luisa Biondi

Circa Diatech Pharmacogenetics

Questo autore non ha riempito alcun dettaglio.
Finora Diatech Pharmacogenetics ha creato 1081 post nel blog.

12 11, 2016

Caterina Marchiò et al., Liquoral liquid biopsy in neoplastic meningitis enables molecular diagnosis and mutation tracking: a proof of concept. Neuro-Oncology

Diatech Pharmacogenetics2017-08-07T08:59:51+02:00

8 11, 2016

Federico Pessina et al., Role of surgical resection in recurrent glioblastoma: prognostic factors and outcome evaluation in an observational study. Journal of Neuro-Oncology

Diatech Pharmacogenetics2017-08-07T10:07:10+02:00

8 11, 2016

Harriet Johansson et al., Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial. Breast Cancer Research

Diatech Pharmacogenetics2017-08-08T12:52:01+02:00

4 11, 2016

PMI DAY-INDUSTRIAMOCI – 7° GIORNATA NAZIONALE DELLE PMI

Diatech Pharmacogenetics2017-08-21T10:30:29+02:00

26 10, 2016

Annemarie Boleij et al., RAS testing practices and RAS mutation prevalence among patients with metastatic colorectal cancer: results from a Europe-wide survey of pathology centres. BMC Cancer

Diatech Pharmacogenetics2017-08-08T12:50:48+02:00

11 10, 2016

Giovanna De Maglio et al., Management optimization of non small cell lung cancer (NSCLC) specimens. A single institution experience with a multiplexed mass spectrometry approach. Annals of Oncology

Diatech Pharmacogenetics2017-08-07T15:57:52+02:00

11 10, 2016

Annarita Destro et al., The impact of mass spectrometry multigenic platform on the management of metastatic colorectal patients. Annals of Oncology

Diatech Pharmacogenetics2017-08-07T16:00:55+02:00

11 10, 2016

Elisa Chiadini et al., Frequency of driver mutations in EGFR wt NSCLC using mass spectrometry: Experience of Area Vasta Romagna. Annals of Oncology

Diatech Pharmacogenetics2017-08-07T15:43:23+02:00

1 10, 2016

Véronique Quilien et al., P06.13?A low baseline blood neutrophil count and a high percentage of Treg among leucocytes are associated with an increased overall survival of recurrent high-grade glioma patients treated with Bevacizumab. Neuro Oncology

Diatech Pharmacogenetics2017-08-07T16:22:33+02:00

1 10, 2016

Marie Duhamel et al., P06.11 Classification of high-grade glioma using Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry imaging (MALDI MSI): interim results of the GLIOMIC study. Neuro Oncology

Diatech Pharmacogenetics2017-12-04T14:36:51+01:00

Precedente 333435 Successivo